Literature DB >> 17610563

Orthopaedic limb salvage with a mega prosthesis in a patient with haemophilia A and inhibitors - a case report.

U C Stumpf1, C Eberhardt, A A Kurth.   

Abstract

Inhibitors against FVIII or FIX in patients with haemophilia are a common and serious complication. Until recently, elective surgery was associated with major bleeding despite the availability of a sufficient substitution therapy. We report about the major orthopaedic reconstruction of the right limb in a patient with severe haemophilia A and inhibitors. This reconstruction was the after effect of a traumatic periprosthetic fracture of the right femur after total knee replacement 6 months ago. This fracture could be stabilized by internal fixation. Two months later, a non-traumatic femur fracture occurred. Therefore, we removed the distal part of the femur and the joint replacement, and implanted a custom made tumour prosthesis (Type MUTARS (c), Münster). These three successive operations, which included emergency and elective surgery, were performed within 8 months. This is, to the best of our knowledge, the first patient with inhibitors undergoing such a complicated reconstruction of a limb. We conclude that successful elective orthopaedic surgery could be accomplished safely in this patient with high responding inhibitors using recombinant FVIIa. After a follow-up of 9 months, no major complications were seen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610563     DOI: 10.1111/j.1365-2516.2007.01476.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

Review 1.  The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.

Authors:  Giancarlo Castaman
Journal:  Blood Transfus       Date:  2017-05-16       Impact factor: 3.443

2.  Risk Factors for Amputation in the Surgical Treatment of Hemophilic Osteoarthropathy: A 20-Year Single-Center Report.

Authors:  Yiming Xu; Bin Feng; Wei Zhu; Yingjie Wang; Xisheng Weng
Journal:  Pain Res Manag       Date:  2022-03-28       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.